These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 27406088)
1. A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia. Yee KW; Chen HW; Hedley DW; Chow S; Brandwein J; Schuh AC; Schimmer AD; Gupta V; Sanfelice D; Johnson T; Le LW; Arnott J; Bray MR; Sidor C; Minden MD Invest New Drugs; 2016 Oct; 34(5):614-24. PubMed ID: 27406088 [TBL] [Abstract][Full Text] [Related]
2. Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML. Jeon JY; Zhao Q; Buelow DR; Phelps M; Walker AR; Mims AS; Vasu S; Behbehani G; Blachly J; Blum W; Klisovic RB; Byrd JC; Garzon R; Baker SD; Bhatnagar B Invest New Drugs; 2020 Apr; 38(2):340-349. PubMed ID: 31102119 [TBL] [Abstract][Full Text] [Related]
3. Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study. Usuki K; Sakura T; Kobayashi Y; Miyamoto T; Iida H; Morita S; Bahceci E; Kaneko M; Kusano M; Yamada S; Takeshita S; Miyawaki S; Naoe T Cancer Sci; 2018 Oct; 109(10):3235-3244. PubMed ID: 30039554 [TBL] [Abstract][Full Text] [Related]
4. Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors. Diamond JR; Bastos BR; Hansen RJ; Gustafson DL; Eckhardt SG; Kwak EL; Pandya SS; Fletcher GC; Pitts TM; Kulikowski GN; Morrow M; Arnott J; Bray MR; Sidor C; Messersmith W; Shapiro GI Clin Cancer Res; 2011 Feb; 17(4):849-60. PubMed ID: 21131552 [TBL] [Abstract][Full Text] [Related]
5. Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation. Fathi AT; Blonquist TM; Hernandez D; Amrein PC; Ballen KK; McMasters M; Avigan DE; Joyce R; Logan EK; Hobbs G; Brunner AM; Joseph C; Perry AM; Burke M; Behnan T; Foster J; Bergeron MK; Moran JA; Ramos AY; Som TT; Rae J; Fishman KM; McGregor KL; Connolly C; Neuberg DS; Levis MJ Cancer; 2018 Jan; 124(2):306-314. PubMed ID: 28960265 [TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776 [TBL] [Abstract][Full Text] [Related]
7. A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML). Padron E; Dezern A; Andrade-Campos M; Vaddi K; Scherle P; Zhang Q; Ma Y; Balasis ME; Tinsley S; Ramadan H; Zimmerman C; Steensma DP; Roboz GJ; Lancet JE; List AF; Sekeres MA; Komrokji RS; Clin Cancer Res; 2016 Aug; 22(15):3746-54. PubMed ID: 26858309 [TBL] [Abstract][Full Text] [Related]
8. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Roboz GJ; Giles FJ; List AF; Cortes JE; Carlin R; Kowalski M; Bilic S; Masson E; Rosamilia M; Schuster MW; Laurent D; Feldman EJ Leukemia; 2006 Jun; 20(6):952-7. PubMed ID: 16617323 [TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial. Papadopoulos KP; Ben-Ami E; Patnaik A; Trone D; Li J; Demetri GD BMC Cancer; 2018 Aug; 18(1):790. PubMed ID: 30081867 [TBL] [Abstract][Full Text] [Related]
10. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Jain N; Curran E; Iyengar NM; Diaz-Flores E; Kunnavakkam R; Popplewell L; Kirschbaum MH; Karrison T; Erba HP; Green M; Poire X; Koval G; Shannon K; Reddy PL; Joseph L; Atallah EL; Dy P; Thomas SP; Smith SE; Doyle LA; Stadler WM; Larson RA; Stock W; Odenike O Clin Cancer Res; 2014 Jan; 20(2):490-8. PubMed ID: 24178622 [TBL] [Abstract][Full Text] [Related]
11. Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia. Fathi AT; Wander SA; Blonquist TM; Brunner AM; Amrein PC; Supko J; Hermance NM; Manning AL; Sadrzadeh H; Ballen KK; Attar EC; Graubert TA; Hobbs G; Joseph C; Perry AM; Burke M; Silver R; Foster J; Bergeron M; Ramos AY; Som TT; Fishman KM; McGregor KL; Connolly C; Neuberg DS; Chen YB Haematologica; 2017 Apr; 102(4):719-727. PubMed ID: 28034990 [TBL] [Abstract][Full Text] [Related]
12. A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer. Diamond JR; Eckhardt SG; Pitts TM; van Bokhoven A; Aisner D; Gustafson DL; Capasso A; Sams S; Kabos P; Zolman K; Colvin T; Elias AD; Storniolo AM; Schneider BP; Gao D; Tentler JJ; Borges VF; Miller KD Breast Cancer Res; 2018 Aug; 20(1):82. PubMed ID: 30071865 [TBL] [Abstract][Full Text] [Related]
13. A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia. Lang F; Wunderle L; Badura S; Schleyer E; Brüggemann M; Serve H; Schnittger S; Gökbuget N; Pfeifer H; Wagner S; Ashelford K; Bug G; Ottmann OG BMC Pharmacol Toxicol; 2020 Sep; 21(1):70. PubMed ID: 32993794 [TBL] [Abstract][Full Text] [Related]
14. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721 [TBL] [Abstract][Full Text] [Related]
15. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088 [TBL] [Abstract][Full Text] [Related]
16. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Pratz KW; Cho E; Levis MJ; Karp JE; Gore SD; McDevitt M; Stine A; Zhao M; Baker SD; Carducci MA; Wright JJ; Rudek MA; Smith BD Leukemia; 2010 Aug; 24(8):1437-44. PubMed ID: 20535150 [TBL] [Abstract][Full Text] [Related]
17. A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia. Kantarjian HM; Schuster MW; Jain N; Advani A; Jabbour E; Gamelin E; Rasmussen E; Juan G; Anderson A; Chow VF; Friberg G; Vogl FD; Sekeres MA Am J Hematol; 2017 Jul; 92(7):660-667. PubMed ID: 28370201 [TBL] [Abstract][Full Text] [Related]
18. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577 [TBL] [Abstract][Full Text] [Related]
19. Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Cortes J; Talpaz M; Smith HP; Snyder DS; Khoury J; Bhalla KN; Pinilla-Ibarz J; Larson R; Mitchell D; Wise SC; Rutkoski TJ; Smith BD; Flynn DL; Kantarjian HM; Rosen O; Van Etten RA Haematologica; 2017 Mar; 102(3):519-528. PubMed ID: 27927766 [TBL] [Abstract][Full Text] [Related]
20. A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia. Levis M; Perl A; Schiller G; Fathi AT; Roboz G; Wang ES; Altman J; Rajkhowa T; Ando M; Suzuki T; Subach RA; Maier G; Madden T; Johansen M; Cheung K; Kurman M; Smith C Blood Adv; 2024 May; 8(10):2527-2535. PubMed ID: 38502195 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]